CA2837609C - Method for the diagnosis of gaucher's disease - Google Patents

Method for the diagnosis of gaucher's disease Download PDF

Info

Publication number
CA2837609C
CA2837609C CA2837609A CA2837609A CA2837609C CA 2837609 C CA2837609 C CA 2837609C CA 2837609 A CA2837609 A CA 2837609A CA 2837609 A CA2837609 A CA 2837609A CA 2837609 C CA2837609 C CA 2837609C
Authority
CA
Canada
Prior art keywords
sample
biomarker
subject
level
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2837609A
Other languages
English (en)
French (fr)
Other versions
CA2837609A1 (en
Inventor
Arndt Rolfs
Hermann Mascher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centogene GmbH
Original Assignee
Centogene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44652046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2837609(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centogene GmbH filed Critical Centogene GmbH
Publication of CA2837609A1 publication Critical patent/CA2837609A1/en
Application granted granted Critical
Publication of CA2837609C publication Critical patent/CA2837609C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2442—Chitinase (3.2.1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2837609A 2011-06-06 2012-06-06 Method for the diagnosis of gaucher's disease Active CA2837609C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11004597A EP2533051A1 (en) 2011-06-06 2011-06-06 Method for the diagnosis of Gaucher's disease
EP11004597.8 2011-06-06
PCT/EP2012/002409 WO2012167925A1 (en) 2011-06-06 2012-06-06 Method for the diagnosis of gaucher's disease

Publications (2)

Publication Number Publication Date
CA2837609A1 CA2837609A1 (en) 2012-12-13
CA2837609C true CA2837609C (en) 2023-04-18

Family

ID=44652046

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837609A Active CA2837609C (en) 2011-06-06 2012-06-06 Method for the diagnosis of gaucher's disease

Country Status (15)

Country Link
US (3) US10859580B2 (enExample)
EP (4) EP2533051A1 (enExample)
JP (2) JP6120832B2 (enExample)
CN (1) CN103582818B (enExample)
AU (2) AU2012266768B2 (enExample)
BR (1) BR112013031431B1 (enExample)
CA (1) CA2837609C (enExample)
DK (2) DK3318881T3 (enExample)
ES (2) ES2820361T3 (enExample)
IL (2) IL229607B (enExample)
NO (1) NO2718725T3 (enExample)
PL (2) PL3318881T3 (enExample)
PT (2) PT3318881T (enExample)
RU (1) RU2666952C2 (enExample)
WO (1) WO2012167925A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007494A (es) * 2012-12-11 2015-12-15 Centogene Ag Metodo para diagnosticar leucodistrofia metacromatica.
WO2015121855A1 (en) * 2014-02-11 2015-08-20 Yeda Research And Development Co. Ltd. Marker of neuropathic gaucher's disease and methods of use thereof
CN105463085A (zh) * 2015-12-11 2016-04-06 上海新培晶医学检验所有限公司 一种检测戈谢病gba基因突变的试剂盒及其检测方法
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
RU2629626C1 (ru) * 2016-10-05 2017-08-30 Федеральное государственное автономное учреждение "Научный центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "НЦЗД" Минздрава России) Способ оценки эффективности лечения болезни Гоше у детей
CA3201604A1 (en) 2020-12-08 2022-06-16 Todd Frank OVOKAITYS Methods and systems for increased production of stem cells
IL317112A (en) * 2022-06-01 2025-01-01 Univ Antwerpen Method for detecting biomarkers of lysosomal storage disease and kits for performing the method
WO2024211616A1 (en) * 2023-04-04 2024-10-10 Ovokaitys Todd Frank Methods and systems for improved therapies of genetic diseases using photo-activated allogenic stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
UA63743A (en) * 2003-06-09 2004-01-15 Kyiv P Shupyk Medical Academy Method for diagnosing gaucher disease
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
ES2485369T3 (es) 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
DK2040548T3 (da) * 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
MX2009011055A (es) 2007-04-13 2010-01-13 Amicus Therapeutics Inc Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos.
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CN104383556B (zh) * 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
AU2009314447A1 (en) * 2008-11-14 2010-05-20 Neuraltus Pharmaceuticals, Inc. Compositions and methods for the treatment of altered alpha-synuclein function

Also Published As

Publication number Publication date
RU2018129872A3 (enExample) 2021-11-08
IL260078A (en) 2018-07-31
EP3742168A1 (en) 2020-11-25
CN103582818A (zh) 2014-02-12
JP6120832B2 (ja) 2017-04-26
IL229607A0 (en) 2014-01-30
BR112013031431A2 (pt) 2016-12-13
RU2013158667A (ru) 2015-07-20
AU2017232226B2 (en) 2019-12-19
US20140187439A1 (en) 2014-07-03
US20180259538A1 (en) 2018-09-13
PT2718725T (pt) 2018-03-07
PL3318881T3 (pl) 2021-02-08
RU2666952C2 (ru) 2018-09-13
NO2718725T3 (enExample) 2018-05-12
ES2659753T3 (es) 2018-03-19
JP2017161528A (ja) 2017-09-14
EP2718725B1 (en) 2017-12-13
BR112013031431B1 (pt) 2023-02-07
AU2012266768B2 (en) 2017-06-29
CN103582818B (zh) 2018-06-05
JP2014517308A (ja) 2014-07-17
RU2018129872A (ru) 2019-03-15
PL2718725T3 (pl) 2018-06-29
IL260078B (en) 2020-10-29
DK3318881T3 (da) 2020-09-28
EP2718725A1 (en) 2014-04-16
EP3318881B1 (en) 2020-07-15
EP3318881A1 (en) 2018-05-09
AU2017232226A1 (en) 2017-10-12
US10859580B2 (en) 2020-12-08
WO2012167925A1 (en) 2012-12-13
US20220011321A1 (en) 2022-01-13
CA2837609A1 (en) 2012-12-13
IL229607B (en) 2018-07-31
PT3318881T (pt) 2020-09-16
JP6514256B2 (ja) 2019-05-15
US11092609B2 (en) 2021-08-17
DK2718725T3 (en) 2018-03-26
ES2820361T3 (es) 2021-04-20
EP2533051A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
US11092609B2 (en) Method for the diagnosis of Gaucher's disease
US11841362B2 (en) Method for the diagnosis of Niemann-Pick disease
AU2012266768A1 (en) Method for the diagnosis of Gaucher's disease
EP2997384B1 (en) Method for the diagnosis of niemann-pick disease
HK40033027A (en) Biomarker for gaucher's disease
US20180348239A1 (en) Method for the Diagnosis of Niemann-Pick Disease Using a Biomarker
RU2780331C2 (ru) Способ диагностики болезни гоше
US20260072045A1 (en) Method for detecting lysosomal storage disease biomarkers and kits for performing the method

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170418

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251223

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260330

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260720